Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Oncologist pay and chemotherapy: Buy and bill needs to stop

Robert Pearl, MD
Physician
August 19, 2014
109 Shares
Share
Tweet
Share

Today’s article highlights the lingering problem of physicians buying and selling prescription medications to patients — at a profit.

The medical profession has struggled with this controversial practice  for more than 150 years.

In George Eliot’s 1874 novel “Middlemarch,” an idealistic young doctor named Tertius Lydgate questions the ethics of fellow physicians who make handsome profits prescribing and dispensing their own remedies to the townsfolk. His medical colleagues shun him for it.

Around the same time, the emergence of pharmacists (then called apothecaries) signaled the start of a major advancement in medicine. Pharmacists helped safeguard the delivery of medications to patients. This progress helped communities recognize the inherent conflict in doctors profiting from the medications they dispense.

As a result, medical specialties began abandoning the practice and the conflict. Today, the practice is largely extinct — with a few exceptions. A particularly problematic one: oncology and the in-office provision of chemotherapy.

At present, many oncologists continue the lucrative practice of administering chemotherapy under a “buy and bill” reimbursement scheme.

The origins of buy and bill for cancer drugs

In the 1940s, nitrogen mustard — originally developed as a biological weapon — was discovered to successfully treat Hodgkin’s disease.

Because of the drug’s toxicity, doctors needed special skills and expertise to handle it safely. Cancer specialists quickly learned how to avoid harming patients and themselves during its administration, although the subsequent side effects proved serious.

As manufacturers introduced more chemotherapy drugs, oncologists bought them wholesale. They administered treatments in their offices and billed insurers at higher prices.

In the 1970s, there were still fewer than a dozen chemotherapy agents on the market. Their costs were minimal.

Then, the standard three-drug regimen for breast cancer cost about $250 (roughly $1,000 in today’s money). As a result, the impact of buy and bill on the oncologist’s income was relatively small and the cost to the health care system modest.

By the 1980s and 1990s, however, the number of new cancer drugs increased rapidly. Buy and bill became much more widespread.

Today, not only is there a broad array of agents, but the costs of more recently approved drugs often exceeds $5,000 to $10,000 per month.

Private insurance companies today have little choice but to pay for what is prescribed. As a result, many oncologists have substantially increased their practice income with reimbursements from reselling the drugs they administer to patients.

Medicare has used a different approach to payment, but also enabled physicians to profit from buy and bill.

Unlike commercial insurers, Medicare employed an average wholesale price (AWP) set by manufacturers. They used it as a reference point for what doctors should charge. AWP is akin to a suggested retail price and is typically much higher than the actual price physicians paid to acquire the drugs.

The result of this buy and resell practice contributed to a rapid escalation in cost of cancer care — both to insurers and public payers like Medicare — with minimal changes in cancer survival rates.

Of course, oncologists staunchly defended the markup, arguing that Medicare did not properly reimburse them for their efforts and administrative costs. But when much of one’s income is determined by these clinical decisions, bias was and is inevitable.

Passage of new legislation: A step in the right direction?

Congress attempted to fix the problem with passage of the Medicare Modernization Act (MMA) in 2003.

The new law did not take away physician’s ability to buy chemotherapy drugs, administer them in-office or bill for them. However, it did alter the reimbursement structure.

To bridge the gap between the price physicians pay for drugs and the pay they collect, the MMA developed a reimbursement model based on average sales price (ASP), plus a 6 percent markup and administrative fee.

As part of this legislation, manufacturers are required to report a drug’s ASP to the Centers of Medicare and Medicaid Services (CMS) quarterly to substantiate reimbursements.

This change did not address the problem.

Oncologists maintained their income by altering their practice patterns.

As the reimbursement for established medications decreased, oncologists have chosen to use progressively more expensive chemotherapy drugs with increased frequency of treatment. That’s because under the fee-for-service reimbursement model, each new treatment equals another payment.

It’s difficult, if not impossible, to prove this shift is directly motivated by personal financial gain. But it’s also hard to deny the financial gain that resulted.

Moving away from conflicts of interest

Like other perverse incentives in a fee-for-service scheme, buy and bill creates a conflict between the medical interests of the patient and the economic interests of the physician.

As a nation, we need to move from a buy and bill approach to a system where an oncologist’s income is independent of the drug treatment chosen.

Patients deserve to feel confident in the clinical decisions of their doctors. The drugs an oncologist administers should be determined by,

  1. the type of cancer
  2. the scientific data on the efficacy of treatment
  3. patient preference

For every clinical specialty, the interests of the patient need to come first. A patient’s cancer treatment deserves to be at the top of the list.

Robert Pearl is a physician and CEO, The Permanente Medical Group. This article originally appeared on Forbes.com. 

Prev

A pediatrician's weight loss journey

August 19, 2014 Kevin 3
…
Next

The dilemma of eating locally-sourced foods

August 19, 2014 Kevin 8
…

Tagged as: Medications, Oncology/Hematology

Post navigation

< Previous Post
A pediatrician's weight loss journey
Next Post >
The dilemma of eating locally-sourced foods

More by Robert Pearl, MD

  • The revolutionary Kaiser-Geisinger deal: How health care giants are reshaping the industry and empowering patients

    Robert Pearl, MD
  • Why retail giants will revolutionize American health care

    Robert Pearl, MD
  • ChatGPT: How generative AI is revolutionizing health care

    Robert Pearl, MD

More in Physician

  • Decoding name displays in health care: Privacy, identification, and compliance unveiled

    Deepak Gupta, MD
  • Master time management with 7 productivity strategies for optimal results

    Farzana Hoque, MD
  • The tragic story of Mr. G: a painful journey towards understanding suicide

    William Lynes, MD
  • The escalating violence in health care workplaces: a critical problem facing the nation’s health care system

    Harry Severance, MD
  • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

    Howard Smith, MD
  • Why allowing yourself to embrace discomfort is necessary for personal growth

    Jillian Rigert, MD, DMD
  • Most Popular

  • Past Week

    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Physician entrepreneurs offer hope for burned out doctors

      Cindy Rubin, MD | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
  • Past 6 Months

    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
  • Recent Posts

    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
    • Empowering Black nurses for lasting change [PODCAST]

      The Podcast by KevinMD | Podcast
    • Master time management with 7 productivity strategies for optimal results

      Farzana Hoque, MD | Physician
    • Proposed USPSTF guideline update: Advocating for earlier breast cancer screening at age 40

      Hoag Memorial Hospital Presbyterian | Conditions
    • The rising threat of lung cancer in Asian American female nonsmokers

      Alice S. Y. Lee, MD | Conditions
    • The tragic story of Mr. G: a painful journey towards understanding suicide

      William Lynes, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 37 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer
  • What Was Tied to Lower Long COVID Risk?
  • Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer
  • Two-Drug Combo Wins for Refractory Gout
  • First-in-Class Sjogren's Drug Passes Mid-Stage Test

Meeting Coverage

  • Novel Anti-HER2 Drugs 'Impressive' in Advanced Biliary Cancer
  • Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer
  • Two-Drug Combo Wins for Refractory Gout
  • First-in-Class Sjogren's Drug Passes Mid-Stage Test
  • Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer
  • Most Popular

  • Past Week

    • The power of coaching for physicians: transforming thoughts, changing lives

      Kim Downey, PT | Conditions
    • The hidden factor in physician burnout: How the climate crisis is contributing to the erosion of well-being

      Elizabeth Cerceo, MD | Physician
    • Physician entrepreneurs offer hope for burned out doctors

      Cindy Rubin, MD | Physician
    • We need a new Hippocratic Oath that puts patient autonomy first

      Jeffrey A. Singer, MD | Physician
    • Boxing legends Tyson and Foreman: powerful lessons for a resilient and evolving health care future

      Harvey Castro, MD, MBA | Physician
    • Is chaos in health care leading us towards socialized medicine? How physician burnout is a catalyst.

      Howard Smith, MD | Physician
  • Past 6 Months

    • Breaking point: the 5 reasons American doctors are dreaming of walking away from medicine

      Amol Shrikhande, MD | Physician
    • It’s time to replace the 0 to 10 pain intensity scale with a better measure

      Mark Sullivan, MD and Jane Ballantyne, MD | Conditions
    • “Is your surgeon really skilled? The hidden threat to public safety in medicine.

      Gene Uzawa Dorio, MD | Physician
    • Unveiling the hidden damage: the secretive world of medical boards

      Alan Lindemann, MD | Physician
    • Breaking the cycle of racism in health care: a call for anti-racist action

      Tomi Mitchell, MD | Policy
    • Revolutionize your practice: the value-based care model that reduces physician burnout

      Chandravadan Patel, MD | Physician
  • Recent Posts

    • Decoding name displays in health care: Privacy, identification, and compliance unveiled

      Deepak Gupta, MD | Physician
    • Empowering Black nurses for lasting change [PODCAST]

      The Podcast by KevinMD | Podcast
    • Master time management with 7 productivity strategies for optimal results

      Farzana Hoque, MD | Physician
    • Proposed USPSTF guideline update: Advocating for earlier breast cancer screening at age 40

      Hoag Memorial Hospital Presbyterian | Conditions
    • The rising threat of lung cancer in Asian American female nonsmokers

      Alice S. Y. Lee, MD | Conditions
    • The tragic story of Mr. G: a painful journey towards understanding suicide

      William Lynes, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Oncologist pay and chemotherapy: Buy and bill needs to stop
37 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...